Hi @elpaso96 -- note that the on-market buy-back for ProMedicus, which permits them to buy back up to 10% of all shares on issue, won't necessarily be acted on. It's just a capital management option that management like to have open.
For example, they announced the same thing last year but actually bought zero shares back over the period (see second page of the latest announcement). I think this was sensible, as a buy-back really only makes sense when (a) there is no better use for the capital, and (b) shares are trading below their intrinsic value.
As such, I wouldn't rely on it to support the price. But agree it's a good option for management if they use it wisely.